Guided Therapeutics

Guided Therapeutics EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Guided Therapeutics (GTHP) as of Oct 26, 2026 is -25.04. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -23.96 — a change of 4.50% (lower).

EV/FCF

-25.04

YoY

4.50%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Guided Therapeutics is 2025 -25.04 . EV/FCF (Enterprise Value to Free Cash Flow) of Guided Therapeutics was 2024 -23.96 . It decreases by 4.50% lower compared to the previous year.

The Guided Therapeutics EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-19.83 USD
Jan 1, 2019
-33.87 USD
Jan 1, 2020
-14.59 USD
Jan 1, 2021
-17.55 USD
Jan 1, 2022
-18.46 USD
Jan 1, 2023
-15.61 USD
Jan 1, 2024
-23.96 USD
Jan 1, 2025
-25.04 USD
The Guided Therapeutics EV/FCF history
YEAREV/FCFYoY
-25.04+4.50%
-23.96+53.47%
-15.61-15.43%
-18.46+5.21%
-17.55+20.27%
-14.59-56.92%
-33.87+70.79%
-19.83-15.11%
-23.36+36.67%
-17.10+145.24%
-6.97+53.28%
-4.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics, Inc. develops medical devices focused on cancer detection using biophotonics. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device for cervical cancer screening and triage. LuViva analyzes reflected and fluorescent light after scanning the cervix with light, offering an alternative to conventional tests. The firm targets healthcare providers and clinics seeking point-of-care solutions for cervical cancer detection. LuViva is designed for two main applications: as a screening tool for early detection of cervical cancer and precancers, and as a triage method to reduce unnecessary follow-up procedures. The company focuses on selling and marketing this device to medical facilities, emphasizing its painless, non-invasive nature and point-of-care functionality. Guided Therapeutics conducts limited clinical studies using its biophotonic technology to support the device's efficacy. The business model centers on the commercialization of LuViva, with the company developing prototypes and conducting clinical studies to validate its biophotonic detection method. Guided Therapeutics aims to position LuViva as a standard in cervical cancer screening, targeting healthcare providers who prioritize non-invasive, efficient diagnostic tools. The firm's revenue comes from the sale of LuViva devices and related services to medical institutions. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Guided Therapeutics is -25.04 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Guided Therapeutics changed from -23.96 to -25.04, representing a 4.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Guided Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Guided Therapeutics

All Key Metrics — Guided Therapeutics